NCT03950830View on ClinicalTrials.gov

Disulfiram and Cisplatin in Refractory TGCTs.

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 14, 2019

Primary Completion Date

September 30, 2021

Study Completion Date

January 31, 2022

Conditions
Germ Cell Tumor
Interventions
DRUG

Disulfiram

Disulfiram 400mg daily, continuously

Trial Locations (1)

83310

National Cancer Institute, Bratislava

All Listed Sponsors
lead

National Cancer Institute, Slovakia

OTHER_GOV

NCT03950830 - Disulfiram and Cisplatin in Refractory TGCTs. | Biotech Hunter | Biotech Hunter